Eli Lilly's Foundayo, a daily weight-loss pill, has received approval for use in the UK, marking it as the first such approval in Europe. The medication is intended for individuals with obesity and type 2 diabetes, but its availability on the NHS remains uncertain as it requires further evaluation for weight loss treatment recommendations.
While patients can obtain Foundayo through private prescriptions, Eli Lilly plans to seek NHS endorsement for its weight-loss application. Experts highlight its potential affordability compared to existing treatments, which could enhance access for patients.
Watch for Eli Lilly's next steps in securing NHS endorsement for Foundayo as a weight-loss treatment. Its affordability could reshape access to obesity management in the UK, especially for those transitioning from injections. Patient outcomes will be key in upcoming evaluations.